Lipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCNFree Report) in a research note issued to investors on Friday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners assumed coverage on Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target for the company.

Get Our Latest Stock Analysis on LPCN

Lipocine Price Performance

Shares of Lipocine stock opened at $4.37 on Friday. The firm has a market cap of $23.38 million, a price-to-earnings ratio of -5.75 and a beta of 1.23. The stock’s 50-day moving average is $4.88 and its 200-day moving average is $4.98. Lipocine has a one year low of $3.20 and a one year high of $11.79.

Lipocine (NASDAQ:LPCNGet Free Report) last released its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. On average, equities analysts expect that Lipocine will post -0.78 EPS for the current year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in Lipocine Inc. (NASDAQ:LPCNFree Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

(Get Free Report)

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

See Also

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.